Granted Patent
B2
US 12,409,199 · App. 18/639,285 · Granted Sep 9, 2025
Methods of treating endometriosis and other noncancer gynecological disorders with hemp extract
Inventors:
Alexandra M. Capano (Philadelphia, PA); Pradeep Singh Tanwar (Fletcher, AU); Alex Nance (Georgetown, KY)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method for treating a noncancerous gynecological disorder comprising: administering to a patient an effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.
Claims (11)
1. A method of treating endometriosis, symptoms associated with endometriosis, or both, the method comprising administering an effective amount of a composition to a patient, said composition comprising a carrier of between 1% and 99% by weight, said composition comprising a cannabis extract (CE) wherein the CE comprises cannabidiol (CBD) from about 20% to about 99.9% by weight of the CE, the CBD extracted from a Cannabaceae plant as a full spectrum hemp extract (FSHE) or a broad spectrum hemp extract (BSHE), said CE delivered within the carrier to create the composition having a pH between 3.5 and 6.
2. The method of claim 1 wherein the CE is administered to the patient as an oral form, oromucosal form, nasal form, rectal form, intravaginal form, injectable form, or combinations thereof.
3. The method of claim 1 wherein the CE further comprises cannabidiolic acid (CBDA) at a concentration of between 0.1% and 10%.
4. The method of claim 1 wherein the effective amount of CE comprises between 25 mg and 4,250 mg of CBD per dose.
5. The method of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.
6. The method of claim 1 wherein the CE is administered orally using an oil or a fat as the carrier.
7. The method of claim 1 further comprising administering the CE concomitantly with a second therapeutic agent.
8. The method of claim 7 wherein the second therapeutic agent is a hormone, gonadotrophin-releasing hormone, progestin, an aromatase inhibitor, a chemotherapeutic agent, or combinations thereof.
9. The method of claim 1 wherein the CE further comprises from about 0.01% to about 0.3% by weight of Δ-9-tetrahydrocannabinol (Δ 9 -THC).
10. The method of claim 1 wherein the CE comprises from about 70% to about 99.9% by weight of CBD.
11. The method of claim 1 wherein administering comprises administering orally up to three times per day.
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 3, 2025
From: ECOFIBRE USA, INC.
To: DOVE INNOVATION PTY LIMITED
Reel/Frame 072141/0535 →
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE OF ASSIGNOR ALEXANDRA M. CAPANO PREVIOUSLY RECORDED ON REEL 67162 FRAME 910. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST.
Recorded Apr 22, 2024
From: CAPANO, ALEXANDRA M.
To: ECOFIBRE USA INC.
Reel/Frame 067176/0145 →
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE OF ASSIGNOR PRADEEP SINGH TANWAR PREVIOUSLY RECORDED ON REEL 67162 FRAME 906. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST.
Recorded Apr 22, 2024
From: TANWAR, PRADEEP SINGH
To: THE UNIVERSITY OF NEWCASTLE
Reel/Frame 067176/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 19, 2024
From: TANWAR, PRADEEP SINGH
To: THE UNIVERSITY OF NEWCASTLE
Reel/Frame 067162/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 19, 2024
From: CAPANO, ALEXANDRA M.
To: ECOFIBRE USA INC.
Reel/Frame 067162/0910 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 19, 2024
From: NANCE, ALEX
To: ECOFIBRE USA INC.
Reel/Frame 067164/0351 →
Continuity (6)
Provisional Application
63263022
· Oct 26, 2021
Provisional Application
63263020
· Oct 26, 2021
Provisional Application
63263026
· Oct 26, 2021
References Cited (105)
US 20100273895A1
· Stinchcomb et al.
· 2010
[cited by applicant]
US 20110086113A1
· Velasco Diez et al.
· 2011
[cited by applicant]
US 20200253919A1
· Raz et al.
· 2020
[cited by applicant]
US 20200408740A1
· Ballan et al.
· 2020
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210068444A1
· Alarcon et al.
· 2021
[cited by applicant]
US 20210069608A1
· Galyuk
· 2021
[cited by applicant]
US 20210128521A1
· Palaio
· 2021
[cited by applicant]
US 20210145764A1
· Lephart
· 2021
[cited by applicant]
US 20220000774A1
· Dely
· 2022
[cited by applicant]
US 20220054429A1
· Nathan et al.
· 2022
[cited by applicant]
US 20220062224A1
· Gubler et al.
· 2022
[cited by applicant]
US 20220248619A1
· Kleidon
· 2022
[cited by applicant]
US 20220253919A1
· Denner
· 2022
[cited by applicant]
US 20230015268A1
· Altman et al.
· 2023
[cited by applicant]
US 20230355645A1
· Storch et al.
· 2023
[cited by applicant]
CN 108433880A
· 2018
[cited by applicant]
CN 110063953A
· 2019
[cited by applicant]
EP 3368024A1
· 2018
[cited by applicant]
EP 3449992A1
· 2019
[cited by applicant]
EP 3544598A1
· 2019
[cited by applicant]
EP 3915550A1
· 2021
[cited by applicant]
EP 3937914A1
· 2022
[cited by applicant]
GB 2516335A
· 2015
[cited by applicant]
RU 2745687C1
· 2021
[cited by examiner]
WO WO2013165251A1
· 2013
[cited by applicant]
WO WO2014057067A1
· 2014
[cited by applicant]
WO WO2016187679A1
· 2016
[cited by applicant]
WO WO2017072773A1
· 2017
[cited by applicant]
WO WO2018167038A1
· 2018
[cited by applicant]
WO WO2019003163A2
· 2019
[cited by applicant]
WO WO2019034113A1
· 2019
[cited by applicant]
WO WO2019003163A3
· 2019
[cited by examiner]
WO WO2019106652A1
· 2019
[cited by applicant]
WO WO2019145552A1
· 2019
[cited by applicant]
WO WO2019195943A1
· 2019
[cited by applicant]
WO WO2019222459A1
· 2019
[cited by applicant]
WO WO2020036655A9
· 2020
[cited by applicant]
WO WO2020163775A1
· 2020
[cited by applicant]
WO WO2020165878A1
· 2020
[cited by applicant]
WO WO2020183455A1
· 2020
[cited by applicant]
WO WO2020194237A1
· 2020
[cited by applicant]
WO WO2020209902A1
· 2020
[cited by applicant]
WO WO2021011790A1
· 2021
[cited by applicant]
WO WO2021016718A1
· 2021
[cited by applicant]
WO WO2021028646A1
· 2021
[cited by applicant]
WO WO2021099792A1
· 2021
[cited by applicant]
WO WO2021130728A1
· 2021
[cited by applicant]
WO WO2021158251A1
· 2021
[cited by applicant]
WO WO2021235977A1
· 2021
[cited by applicant]
WO WO2021240510A1
· 2021
[cited by applicant]
WO WO2021245522A1
· 2021
[cited by applicant]
WO WO2022013854A1
· 2022
[cited by applicant]
WO WO2022016160A1
· 2022
[cited by applicant]
WO WO2022018708A1
· 2022
[cited by applicant]
WO WO2022105952A1
· 2022
[cited by applicant]
WO WO2022118303A1
· 2022
[cited by applicant]
WO WO2022144878A1
· 2022
[cited by applicant]
WO WO2022165349A1
· 2022
[cited by applicant]
WO WO2022165439A1
· 2022
[cited by applicant]
WO WO2022201043A1
· 2022
[cited by applicant]
WO WO2022215071A1
· 2022
[cited by applicant]
WO WO2022225658A1
· 2022
[cited by applicant]
WO WO2023287742A1
· 2023
[cited by applicant]
WO WO2023014818A2
· 2023
[cited by applicant]
WO WO2023062634A1
· 2023
[cited by applicant]
Marinotti et al, Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science. Journal of Dietary Supplements, (Sep. 2, 2020) vol. 17, No. 5, Sp. Iss. SI.). (Year: 2020).
[cited by examiner]
International Search Report issued in International Application No. PCT/US2022/078698 dated Dec. 14, 2022.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2022/078701 dated Feb. 15, 2023.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2022/078691 dated Jan. 30, 2023.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2022/078693 dated Jan. 30, 2023.
[cited by applicant]
Armour, et al., “Self-Management Strategies Amongst Australian Women With Endometriosis: A National Online Survey”, BMC Complementary and Alternative Medicine, vol. 19, No. 1, art. 17, Jan. 15, 2019, 1-8.
[cited by applicant]
Escudero-Lara, et al., “Disease-Modifying Effects of Natural Δ
[cited by applicant]
Fonseca, et al., “Cannabinoid-Induced Cell Death in Endometrial Cancer Cells: Involvement of TRPV1 Receptors in Apoptosis”, Journal of Physiology and Biochemistry, vol. 74, No. 2, Feb. 13, 2018, 261-272.
[cited by applicant]
Fraguas-Sánchez, et al., “Enhancing Ovarian Cancer Conventional Chemotherapy Through the Combination With Cannabidiol Loaded Microparticles”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 154, Jul. 17, 20…
[cited by applicant]
Go, et al., “Cannabidiol Enhances Cytotoxicity of Anti-Cancer Drugs in Human Head and Neck Squamous Cell Carcinoma”, Scientific Reports, vol. 10, No. 1, art. 20622, Nov. 26, 2020, 1-11.
[cited by applicant]
Griffiths, et al., “Cannabidiol Suppresses 3-Dimensional Ovarian Cancer Growth and May Enhance Potency of Classic and Epigenetic Therapies”, Gynecologic Oncology, vol. 162, suppl. 1, Abstracts for the 2021 Society of Gy…
[cited by applicant]
Hazekamp, et al., “Preparative Isolation of Cannabinoids from Cannabis sativa by Centrifugal Partition Chromatography”, Journal of Liquid Chromatography & Related Technologies, vol. 27, No. 15, 2004, 2421-2439.
[cited by applicant]
Jaidee, et al., “Kinetics of Cbd, Δ
[cited by applicant]
Jin, et al., “Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots”, Frontiers in Plant Science, vol. 12, ar…
[cited by applicant]
Kenyon, et al., “Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-Grade Synthetic Cannabidiol”, Anticancer Research, vol. 38, No. 10, Oct. 1, 2018, 5831-5835.
[cited by applicant]
Lazarjani, et al., “Processing and Extraction Methods of Medicinal Cannabis: A Narrative Review”, Journal of Cannabis Research, vol. 3, art. 32, Jul. 19, 2021, 1-15.
[cited by applicant]
Marinelli, et al., “The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer”, International Journal of Molecular Sciences, vol. 21, No. 15, art. 5409, Jul. 29, 2020, 1-22.
[cited by applicant]
Marinotti, et al., “Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science”, Journal of Dietary Supplements, vol. 17, No. 5, Jun. 16, 2020, 517-526.
[cited by applicant]
Midatech Pharma US Inc., Soltamox® Product Label, Revised Apr. 2019.
[cited by applicant]
Ökten, et al., “Cannabidiol as a Potential Novel Treatment for Endometriosis by Its Anti-Inflammatory and Anti-Oxidative Effects in an Experimental Rat Model”, Human Reproduction, vol. 37, issue supp. 1, Jun. 30, 2022, …
[cited by applicant]
Olivas-Aguirre, et al., “Tamoxifen Sensitizes Acute Lymphoblastic Leukemia Cells to Cannabidiol by Targeting Cyclophilin-D and Altering Mitochondrial Ca
[cited by applicant]
Rais, et al., “Phytochemicals in the Treatment of Ovarian Cancer”, Frontiers in Bioscience-Elite, vol. 9, No. 1, Jan. 1, 2017, 67-75.
[cited by applicant]
Rush, et al., “Cannabidiol: Assessing Activity in Ovarian and Endometrial Carcinoma Cell Lines”, Abstracts for the 2021 Society of Gynecologic Oncology 52nd Annual Meeting on Women's Cancer, Featured Posters 188—Poster …
[cited by applicant]
Sumanasekera, et al., “Hemp Extract With Specific Anti-Cancer Properties Against Ovarian Cancer”, The FASEB Journal Special Issue: Experimental Biology 2021 Meeting Abstracts, vol. 35, No. S1, May 14, 2021, https://doi.…
[cited by applicant]
Van Weelden, et al., “Anti-Estrogen Treatment in Endometrial Cancer: A Systematic Review”, Frontiers in Oncology, vol. 9, art. 359, May 7, 2019, 1-12.
[cited by applicant]
Boretto, et al., “Patient-Derived Organoids From Endometrial Disease Capture Clinical Heterogeneity and Are Amenable to Drug Screening”, Nature Cell Biology, vol. 21, Aug. 1, 2019, 1041-1051.
[cited by applicant]
Fraguas-Sánchez, Ana I., et al., “PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment”, Pharmaceutics, vol. 12, No. 5, art. 439, May 9, 202…
[cited by applicant]